BamSEC and AlphaSense Join Forces
Learn More

Fate Therapeutics Inc.

NASDAQ: FATE    
Share price (12/20/24): $1.68    
Market cap (12/20/24): $191 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 5 pages Amendment No. 4 to Collaboration and Option Agreement
12/34/56
EX-10.1
from 8-K 16 pages Fate Therapeutics, Inc. [Amended and Restated]1 [Director][officer] Indemnification Agreement
12/34/56
EX-10.1
from 8-K 17 pages Fate Therapeutics, Inc. Amended and Restated 2022 Stock Option and Incentive Plan
12/34/56
EX-10.1
from 8-K 17 pages Securities Purchase Agreement
12/34/56
EX-10.42
from 10-K 21 pages Exclusive License Agreement Re: Bcm Blg #[***], Entitled “Chimeric Defense Receptors (Cdrs) for the Selective Targeting of Pathogenic T Cells”
12/34/56
EX-10.41
from 10-K 4 pages Amendment No. 3 to Collaboration and Option Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Fate Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 8-K 3 pages Ono Pharmaceutical Co., Ltd. 8-2, Kyutaromachi 1-Chome, Chuo-Ku, Osaka-Shi 541-8564, Japan Tel : 81-6-6263-5670 Fax : 81-6-6263-2976 November 7, 2022 Fate Therapeutics, Inc. Corporate Headquarters 12278 Scripps Summit Drive San Diego, Ca 92131 United States of America Attention: Mr. Scott Wolchko Re: Amendment to Collaboration and Option Agreement With Respect to Collaboration Candidate 2
12/34/56
EX-10.2
from 10-Q 13 pages Amendment 01 to Collaboration and Option Agreement
12/34/56
EX-10.40
from 10-K 31 pages License Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Fate Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.40
from 10-K 22 pages Patent License Agreement
12/34/56
EX-10.39
from 10-K 4 pages Material contract
12/34/56
EX-10.22
from 10-K 35 pages License Agreement by and Between the Scripps Research Institute, a California Nonprofit Public Benefit Corporation and Fate Therapeutics, Inc. a Delaware Corporation License Agreement
12/34/56
EX-10.21
from 10-K 35 pages License Agreement by and Between the Scripps Research Institute, a California Nonprofit Public Benefit Corporation and Fate Therapeutics, Inc. a Delaware Corporation License Agreement
12/34/56
EX-10.20
from 10-K 35 pages License Agreement by and Between the Scripps Research Institute, a California Nonprofit Public Benefit Corporation and Fate Therapeutics, Inc., a Delaware Corporation License Agreement
12/34/56
EX-10.19
from 10-K 36 pages Whitehead Institute for Biomedical Research and Fate Therapeutics, Inc. Exclusive Patent License Agreement
12/34/56
EX-10.10
from 10-K 7 pages Restricted Stock Unit Award Agreement Under Fate Therapeutics, Inc. Inducement Equity Plan
12/34/56
EX-10.9
from 10-K 10 pages Stock Option Agreement Under Fate Therapeutics, Inc. Inducement Equity Plan
12/34/56
EX-10.8
from 10-K 11 pages Fate Therapeutics, Inc. Amended and Restated Inducement Equity Plan
12/34/56